Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 106
Filter
1.
Eur Heart J Cardiovasc Imaging ; 15(3): 275-83, 2014 Mar.
Article in English | MEDLINE | ID: mdl-23975570

ABSTRACT

AIMS: To study the prognostic value of rapid-acquisition adenosine stress-rest myocardial perfusion scintigraphy (MPS) on a gamma camera using multipinhole collimation and cadmium-zinc-telluride (CZT) detectors. The secondary aim was to assess the diagnostic accuracy of the technique compared with invasive coronary angiography. METHODS AND RESULTS: Retrospective analysis of 1109 consecutive patients undergoing MPS in a routine clinical setting on a high-efficiency multipinhole gamma camera. MPS acquisition, performed with a standard injection of 550 MBq of (99m)Tc-tetrofosmin, required a mean (±SD) scanning time of 322 ± 51 s. The hard cardiac event rate at a median (inter-quartile range) follow-up of 624 (552-699) days was 0.4% (95% CI 0.1-1.1) in patients with no significant perfusion abnormality versus 6.8% (95% CI 4.3-10.7%, P < 0.001) in those with an abnormal scan. In a sub-group of 165 patients, comparison with obstructive coronary artery disease on X-ray angiography gave a sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for rapid-acquisition MPS of 84% (95% CI 74-91), 79% (95% CI 68-87), 82% (95% CI 72-89), 81% (95% CI 70-89), and 82% (95% CI 73-89), respectively. CONCLUSIONS: MPS performed on a CZT solid-state detector camera with multipinhole collimation is an evolutionary development that provides reliable prognostic and diagnostic information, while significantly reducing image acquisition time.


Subject(s)
Cadmium , Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography/methods , Coronary Artery Disease/diagnostic imaging , Gamma Cameras , Myocardial Perfusion Imaging/instrumentation , Tellurium , Zinc , Adult , Aged , Aged, 80 and over , Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography/instrumentation , Cardiology/methods , Cohort Studies , Coronary Angiography/methods , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Myocardial Perfusion Imaging/methods , Prognosis , Proportional Hazards Models , Retrospective Studies , Sensitivity and Specificity , Severity of Illness Index , Young Adult
2.
Exp Physiol ; 94(1): 11-7, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18820004

ABSTRACT

The fundamental mechanism that underlies essential hypertension is a high total peripheral resistance. We review here possible origins of high total peripheral resistance in physiologically hypertensive giraffes, spontaneously hypertensive rats and humans with essential hypertension. We propose that a common link could be reduced brainstem perfusion, as first suggested by Cushing in 1901. Any tendency towards reduction of cerebral blood flow to the cardiovascular control centres in rest and sleep will be prevented by activation of a response arising in the brainstem. The response will proportionately increase systemic blood pressure and return cerebral blood flow to a new homeostatic level. New evidence we review here supports this idea and leads us to suggest that central regulation of blood pressure has two components: the classic Cushing's response, which is a terminal event, and a Cushing's mechanism, which is a physiological mechanism for long-term control of mean arterial pressure. In giraffes, Cushing's mechanism is activated by increasing neck length during growth and subsequent gravitational hypotension that stimulates a rise in basal arterial blood pressure. In man and rats, the mechanism is activated by narrowing of the arteries supplying the brainstem. If we are correct, future successful treatment of essential hypertension in man will include methods of reducing cerebral arterial resistance.


Subject(s)
Blood Pressure/physiology , Brain Stem/physiology , Cerebrovascular Circulation/physiology , Animals , Homeostasis/physiology , Humans , Hypertension/physiopathology , Neck/anatomy & histology , Rats , Ruminants , Species Specificity , Vascular Resistance/physiology
3.
QJM ; 100(11): 715-9, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17951316

ABSTRACT

Much evidence suggests that acute intracerebral haemorrhage usually starts to appear an hour or two after a thromboembolic brain infarct. Intravenous thrombolytic treatment is accepted treatment for acute ischaemic stroke; but all neurologists concur that brain imaging should be performed first, so that thrombolysis can be avoided if bleeding has already started. This article calls into question the current guidelines for the use of thrombolytic treatment in acute stroke. Are they too restrictive?


Subject(s)
Brain Ischemia/drug therapy , Fibrinolytic Agents/therapeutic use , Stroke/drug therapy , Thrombolytic Therapy , Acute Disease , Blood Flow Velocity/physiology , Cadaver , Carotid Arteries/physiology , Cerebral Arteries/physiology , Female , Humans , Male , Practice Guidelines as Topic , Stroke/physiopathology
4.
J Hypertens ; 19(9): 1515-21, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11564969

ABSTRACT

Although it seems obvious that excessive intravascular pressure is the cause of spontaneous intracerebral haemorrhage, the available evidence instead suggests that haemorrhage arises from previous ischaemic damage to the walls of small blood vessels. This interpretation unifies the aetiology of cerebral infarction and intracerebral haemorrhage. It is supported by much pathological evidence and also fits with observations on spontaneous stroke-prone hypertensive rats, which have smaller cerebral arteries than Wistar-Kyoto rats. Ischaemic damage to the brain probably occurs during spontaneous dips in aortic pressure in the presence of atheromatous arterial lesions and arteriolar narrowing by lipohyaline deposits. It may also follow long-lasting arterial spasm provoked by sudden pressure elevations. Local factors, especially unevenness of cerebral perfusion, probably determine the site of an infarct and whether it becomes haemorrhagic or not. In the long term, hypotensive drugs will lessen atheroma deposition. In the short term, they may act by reducing or preventing damaging arteriolar spasm.


Subject(s)
Hypertension/complications , Stroke/etiology , Animals , Cerebral Hemorrhage/complications , Cerebral Hemorrhage/etiology , Cerebral Infarction/etiology , Disease Models, Animal , Genetic Predisposition to Disease , Humans , Hypertension/drug therapy , Models, Cardiovascular , Rats , Rats, Inbred SHR/genetics , Risk Factors , Stroke/prevention & control
5.
Am J Physiol Gastrointest Liver Physiol ; 280(2): G298-307, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11208554

ABSTRACT

Gastrin (G17) has a CCK-B receptor-mediated growth-promoting effect on the AR42J rat acinar cell line. We examined whether G17 inhibits apoptosis induced by serum withdrawal of AR42J cells and CHO-K1 cells stably expressing CCK-B receptors (CHO-K1/CCK-B cells). Cellular apoptosis was measured by flow cytometry and the terminal deoxynucleotidyltransferase-mediated dUTP-FITC nick end-labeling method. Serum withdrawal induced AR42J and CHO-K1/CCK-B cell apoptosis. Addition of 10 nM G17 reversed these effects. We examined the action of G17 (10 nM) on phosphorylation and activation of protein kinase B/Akt, a kinase known to promote cell survival. Akt phosphorylation and activation were measured by kinase assays and Western blots with an anti-phospho-Akt antibody. G17 stimulated Akt phosphorylation and activation. G17 induction of Akt phosphorylation was inhibited by the phosphoinositide 3-kinase (PI 3-kinase) inhibitors LY-294002 (10 microM) and wortmannin (200 nM) but not by the mitogen-activated protein kinase kinase 1 inhibitor PD-98059 (50 microM). To study the role of p38 kinase in G17 signaling to Akt, we examined the effect of G17 on p38 kinase activation and phosphorylation using kinase assays and Western blots with an anti-phospho-p38 kinase antibody. G17 induced p38 kinase activity at doses and with kinetics similar to those observed for Akt induction. The p38 kinase inhibitor SB-203580 inhibited G17 induction of Akt phosphorylation and activation at a concentration (10 microM) 10-fold higher than necessary to block p38 kinase (1 microM), suggesting the possible involvement of kinase activities other than p38 kinase. Transduction of AR42J cells with the adenoviral vector Adeno-dn Akt, which overexpresses an inhibitor of Akt, reversed the antiapoptotic action of G17. In conclusion, G17 promotes AR42J cell survival through the induction of Akt via PI 3-kinase and SB-203580-sensitive kinase activities.


Subject(s)
Apoptosis/drug effects , Gastrins/pharmacology , Protein Serine-Threonine Kinases , Animals , CHO Cells , Cell Line , Cricetinae , DNA Fragmentation , Enzyme Activation/physiology , In Situ Nick-End Labeling , Mitogen-Activated Protein Kinases/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Phosphorylation , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins/physiology , Proto-Oncogene Proteins c-akt , Rats , Receptor, Cholecystokinin B , Receptors, Cholecystokinin/physiology , Signal Transduction/drug effects , Signal Transduction/physiology , p38 Mitogen-Activated Protein Kinases
7.
Biochemistry ; 39(48): 14900-11, 2000 Dec 05.
Article in English | MEDLINE | ID: mdl-11101306

ABSTRACT

To elucidate the molecular basis for the interaction of ligands with the human melanocortin-4 receptor (hMC4R), agonist structure-activity studies and receptor point mutagenesis were performed. Structure-activity studies of [Nle(4), D-Phe(7)]-alpha-melanocyte stimulating hormone (NDP-MSH) identified D-Phe7-Arg8-Trp9 as the minimal NDP-MSH fragment that possesses full agonist efficacy at the hMC4R. In an effort to identify receptor residues that might interact with amino acids in this tripeptide sequence 24 hMC4R transmembrane (TM) residues were mutated (the rationale for choosing specific receptor residues for mutation is outlined in the Results section). Mutation of TM3 residues D122 and D126 and TM6 residues F261 and H264 decreased the binding affinity of NDP-MSH 5-fold or greater, thereby identifying these receptor residues as sites potentially involved in the sought after ligand-receptor interactions. By examination of the binding affinities and potencies of substituted NDP-MSH peptides at receptor mutants, evidence was found that core melanocortin peptide residue Arg8 interacts at a molecular level with hMC4R TM3 residue D122. TM3 mutations were also observed to decrease the binding of hMC4R antagonists. Notably, mutation of TM3 residue D126 to alanine decreased the binding affinity of AGRP (87-132), a C-terminal derivative of the endogenous melanocortin antagonist, 8-fold, and simultaneous mutations D122A/D126A completely abolished AGRP (87-132) binding. In addition, mutation of TM3 residue D122 or D126 decreased the binding affinity of hMC4R antagonist SHU 9119. These results provide further insight into the molecular determinants of hMC4R ligand binding.


Subject(s)
Receptors, Peptide/metabolism , alpha-MSH/analogs & derivatives , Agouti-Related Protein , Amino Acid Sequence , Amino Acids, Cyclic/genetics , Binding Sites , Cysteine/genetics , Humans , Intercellular Signaling Peptides and Proteins , Ligands , Models, Molecular , Molecular Sequence Data , Mutagenesis, Site-Directed , Peptide Fragments/metabolism , Protein Binding , Protein Conformation , Proteins/metabolism , Receptor, Melanocortin, Type 4 , Receptors, Peptide/genetics , Recombinant Proteins/metabolism , Threonine/genetics , alpha-MSH/chemistry , alpha-MSH/metabolism
8.
Regul Pept ; 89(1-3): 19-28, 2000 May 10.
Article in English | MEDLINE | ID: mdl-10771309

ABSTRACT

Gastrin is initially synthesized as a large precursor that requires endoproteolytic cleavage by a prohormone convertase (PC) for bioactivation. Gastric antral G-cells process progastrin at Arg(94)Arg(95) and Lys(74)Lys(75) residues generating gastrin heptadecapeptide (G17-NH(2)). Conversely, duodenal G-cells process progastrin to gastrin tetratriacontapeptide (G34-NH(2)) with little processing at Lys(74)Lys(75). Both tissues express PC1/PC3 and PC2. Previously, we demonstrated that heterologous expression of progastrin in an endocrine cell line that expresses PC1/PC3 and little PC2 (AtT-20) resulted in the formation of G34-NH(2). To confirm that PC1/PC3 was responsible for progastrin processing in AtT-20 cells and capable of processing progastrin in vivo we coexpressed either human wild-type (Lys(74)Lys(75)) or mutant (Arg(74)Arg(75), Lys(74)Arg(75), and Arg(74)Lys(75)) progastrins in AtT-20 cells with two different antisense PC1/PC3 constructs. Coexpression of either antisense construct resulted in a consistent decrease in G34-NH(2) formation. Gastrin mRNA expression and progastrin synthesis were equivalent in each cell line. Although mutation of the Lys(74)Lys(75) site within G34-NH(2) to Lys(74)Arg(75) resulted in the production of primarily G17-NH(2) rather than G34-NH(2), inhibition of PC1/PC3 did not significantly inhibit processing at the Lys(74)Arg(75) site. We conclude that PC1/PC3 is a progastrin processing enzyme, suggesting a role for PC1/PC3 progastrin processing in G-cells.


Subject(s)
Aspartic Acid Endopeptidases/biosynthesis , Gastrins/metabolism , Protein Precursors/metabolism , Protein Processing, Post-Translational , Aspartic Acid Endopeptidases/genetics , Cell Line , Gastrins/genetics , Gene Expression Regulation, Enzymologic , Humans , Proprotein Convertases , Protein Precursors/genetics
10.
Br J Obstet Gynaecol ; 106(10): 1003-5, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10519423
11.
Am J Physiol ; 277(2): R572-81, 1999 08.
Article in English | MEDLINE | ID: mdl-10444566

ABSTRACT

Posttranslational processing of progastrin to a carboxy terminally amidated form (G-NH(2)) is essential for its effect on gastric acid secretion and other biological effects mediated by gastrin/CCK-B receptors. The immediate biosynthetic precursor of G-NH(2), glycine-extended gastrin (G-Gly), does not stimulate gastric acid secretion at physiological concentrations but is found in high concentrations during development. G-NH(2) and G-Gly have potent growth stimulatory effects on gastrointestinal tissues, and G-NH(2) can stimulate proliferation of human kidney cells. Thus we sought to explore the actions of G-NH(2) and G-Gly on the human embryonic kidney cell line HEK 293. HEK 293 cells showed specific binding sites for (125)I-labeled Leu(15)-G17-NH(2) and (125)I-Leu(15)-G(2-17)-Gly. Both G-NH(2) and G-Gly induced a dose-dependent increase in [(3)H]thymidine incorporation, and both peptides together significantly increased [(3)H]thymidine incorporation above the level of either peptide alone. G-NH(2) and G-Gly were detected by radioimmunoassay in serum-free conditioned media. Antibodies directed against G-NH(2) and G-Gly lead to a significant reduction in [(3)H]thymidine incorporation. G-NH(2) but not G-Gly increased intracellular Ca(2+) concentration. We conclude that G-NH(2) and G-Gly act cooperatively via distinct receptors to stimulate the growth of a nongastrointestinal cell line (HEK 293) in an autocrine fashion.


Subject(s)
Gastrins/pharmacology , Kidney/embryology , Binding Sites , Calcium/metabolism , Cell Division/drug effects , Cell Line , Embryo, Mammalian/cytology , Gastrins/genetics , Gastrins/metabolism , Gene Expression , Humans , Immunoblotting , Intracellular Membranes/metabolism , Osmolar Concentration , Receptor, Cholecystokinin B , Receptors, Cholecystokinin/metabolism , Receptors, Glycine/metabolism
12.
Mol Med ; 5(3): 147-59, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10404512

ABSTRACT

BACKGROUND: Since human colon cancers often contain significant quantities of progastrin-processing intermediates, we sought to explore the possibility that the biosynthetic precursor of fully processed amidated gastrin, glycine-extended gastrin, may exert trophic effects on human colonic cancer cells. MATERIALS AND METHODS: Binding of radiolabeled glycine-extended and amidated gastrins was assessed on five human cancer cell lines: LoVo, HT 29, HCT 116, Colo 320DM, and T 84. Trophic actions of the peptides were assessed by increases in [3H]thymidine incorporation and cell number. Gastrin expression was determined by northern blot and radioimmunoassay. RESULTS: Amidated gastrin did not bind to or stimulate the growth of any of the five cell lines. In contrast, saturable binding of radiolabeled glycine-extended gastrin was seen on LoVo and HT 29 cells that was not inhibited by amidated gastrin (10(-6) M) nor by a gastrin/CCKB receptor antagonist (PD 134308). Glycine-extended gastrin induced a dose-dependent increase in [3H]thymidine uptake in LoVo (143 +/- 8% versus control at 10(-10) M) and HT 29 (151 +/- 11% versus control at 10(-10) M) cells that was not inhibited by PD 134308 or by a mitogen-activated protein (MAP) or ERK kinase (MEK) inhibitor (PD 98509). Glycine-extended gastrin did stimulate jun-kinase activity in LoVo and HT 29 cells. The two cell lines expressed the gastrin gene at low levels and secreted small amounts of amidated gastrin and glycine-extended gastrin into the media. CONCLUSIONS: Glycine-extended gastrin receptors are present on human colon cancer cells that mediate glycine-extended gastrin's trophic effects via a MEK-independent mechanism. This suggests that glycine-extended gastrin and its novel receptors may play a role in colon cancer cell growth.


Subject(s)
Colonic Neoplasms/metabolism , Colonic Neoplasms/pathology , DNA-Binding Proteins , Gastrins/metabolism , Gastrins/pharmacology , Mitogen-Activated Protein Kinases , Peptide Fragments/metabolism , Peptide Fragments/pharmacology , Receptors, Cholecystokinin/metabolism , Transcription Factors , Animals , Antineoplastic Agents/pharmacology , Binding Sites , Binding, Competitive , Calcium-Calmodulin-Dependent Protein Kinases/drug effects , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Cell Division/drug effects , Colonic Neoplasms/drug therapy , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Flavonoids/pharmacology , Gastrins/genetics , Gene Expression Regulation/drug effects , Humans , Indoles/pharmacology , JNK Mitogen-Activated Protein Kinases , Meglumine/analogs & derivatives , Meglumine/pharmacology , Protein Processing, Post-Translational , Proto-Oncogene Proteins/drug effects , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/metabolism , Rats , Receptors, Cholecystokinin/drug effects , Recombinant Proteins/drug effects , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Response Elements , Signal Transduction , Tetradecanoylphorbol Acetate/pharmacology , Tumor Cells, Cultured , ets-Domain Protein Elk-1
13.
Med Hypotheses ; 52(3): 209-12, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10362279

ABSTRACT

The many viruses associated with Pagetic osteoclasts could be opportunistic rather than causative. Some mouth bacteria can lyse bone. One (Actinobacillus actinomycetemcomitans) can grow and even multiply inside human cell lines in culture, producing osteolytic materials -- one 62 kDa protein having a potency in the picomolar range. A small focus of this, or of one of the other periodontitis-causing bacteria, in a bone might gradually spread its influence to activate osteoclasts -- the first stage in Paget's disease. The focus in each bone might be small and easily overlooked, as other intracellular bacteria have been in the past.


Subject(s)
Mouth/microbiology , Osteitis Deformans/microbiology , Aggregatibacter actinomycetemcomitans , Humans , Models, Biological , Osteitis Deformans/virology , Osteoclasts/virology , Osteolysis
14.
Am J Physiol ; 276(6): G1363-72, 1999 06.
Article in English | MEDLINE | ID: mdl-10362639

ABSTRACT

Gastrin (G17) has a CCKB receptor-mediated growth-promoting effect on the AR42J rat acinar cell line that is linked to induction of both mitogen-activated protein kinase (MAPK) and c-fos gene expression. We investigated the mechanisms that regulate the growth factor action of G17 on the rat pituitary adenoma cell line GH3. Both AR42J and GH3 cells displayed equal levels of CCKB receptor expression and similar binding kinetics of 125I-labeled G17. G17 stimulation of cell proliferation was identical in both cell lines. G17 stimulation of GH3 cell proliferation was completely blocked by the CCKB receptor antagonist D2 but not by the MEK inhibitor PD-98059 or the protein kinase C inhibitor GF-109203X, which completely inhibited G17 induction of AR42J cell proliferation. G17 induced a c-fos SRE-luciferase reporter gene plasmid more than fourfold in the AR42J cells, whereas it had no effect in the GH3 cells. In contrast to what we observed in the AR42J cells, G17 failed to stimulate MAPK activation and Shc tyrosyl phosphorylation and association with the adapter protein Grb2. Epidermal growth factor induced the MAPK pathway in the GH3 cells, demonstrating the integrity of this signaling system. G17 induced Ca2+ mobilization in both the GH3 and AR42J cells. The calmodulin inhibitor N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide inhibited AR42J cell proliferation by 20%, whereas it completely blocked G17 induction of GH3 cell growth. The Ca2+ ionophore ionomycin stimulated GH3 cell proliferation to a level similar to that observed in response to G17, but it had no effect on AR42J cell proliferation. Thus there are cell type specific differences in the requirement of the MAPK pathway for the growth factor action of G17. Whereas in the AR42J cells G17 stimulates cell growth through activation of MAPK and c-fos gene expression, in the GH3 cells, G17 fails to activate MAPK, and it induces cell proliferation through Ca2+-dependent signaling pathways. Furthermore, induction of Ca2+ mobilization in the AR42J cells appears not to be sufficient to sustain cell proliferation.


Subject(s)
Adaptor Proteins, Signal Transducing , Adaptor Proteins, Vesicular Transport , Adenoma/physiopathology , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Gastrins/physiology , Growth Substances/physiology , Pancreas/physiopathology , Pituitary Neoplasms/physiopathology , Adenoma/metabolism , Adenoma/pathology , Animals , Calcium Signaling/physiology , Cell Division/drug effects , Cell Division/physiology , Cell Line , Enzyme Activation/physiology , Epidermal Growth Factor/pharmacology , Gastrins/metabolism , Gastrins/pharmacology , Gene Expression/drug effects , Pancreas/cytology , Pancreas/metabolism , Phosphorylation , Pituitary Neoplasms/metabolism , Pituitary Neoplasms/pathology , Protein Kinase C/physiology , Proteins/metabolism , Proto-Oncogene Proteins c-fos/genetics , Rats , Receptor, Cholecystokinin B , Receptors, Cholecystokinin/metabolism , Receptors, Cholecystokinin/physiology , Shc Signaling Adaptor Proteins , Src Homology 2 Domain-Containing, Transforming Protein 1
15.
J Biol Chem ; 274(20): 14100-6, 1999 May 14.
Article in English | MEDLINE | ID: mdl-10318826

ABSTRACT

Agouti-related protein (AGRP) is an endogenous antagonist of melanocortin action that functions in the hypothalamic control of feeding behavior. Although previous studies have shown that AGRP binds three of the five known subtypes of melanocortin receptor, the receptor domains participating in binding and the molecular interactions involved are presently unknown. The present studies were designed to examine the contribution of extracytoplasmic domains of the melanocortin-4 receptor (MC4R) to AGRP binding by making chimerical receptor constructs of the human melanocortin-1 receptor (MC1R; a receptor that is not inhibited by AGRP) and the human MC4R (a receptor that is potently inhibited by AGRP). Substitutions of the extracytoplasmic NH2 terminus and the first extracytoplasmic loop (exoloop) of the MC4R with homologous domains of the MC1R had no effect on AGRP (87-132) binding affinity or inhibitory activity (the ability to inhibit melanocortin-stimulated cAMP generation). In contrast, cassette substitutions of exoloops 2 and 3 of the MC4R with the homologous exoloops of the MC1R resulted in a substantial loss of AGRP binding affinity and inhibitory activity. Conversely, the exchange of exoloops 2 and 3 of the MC1R with the homologous exoloops of the MC4R was found to confer AGRP binding and inhibitory activity to the basic structure of the MC1R. Importantly, these substitutions did not affect the ability of the alpha-melanocyte stimulating hormone analogue [Nle4,D-Phe7] melanocyte stimulating hormone to bind or activate the chimeric receptors. These data indicate that exoloops 2 and 3 of the melanocortin receptors are important for AGRP binding.


Subject(s)
Proteins/metabolism , Receptors, Corticotropin/metabolism , Agouti-Related Protein , Amino Acid Sequence , Cytoplasm/metabolism , Humans , Intercellular Signaling Peptides and Proteins , Molecular Sequence Data , Protein Binding , Protein Conformation , Receptor, Melanocortin, Type 4 , Receptors, Melanocortin , Receptors, Peptide/genetics , Receptors, Peptide/metabolism , Recombinant Fusion Proteins/metabolism , Structure-Activity Relationship
16.
J Vasc Surg ; 29(4): 685-93, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10194497

ABSTRACT

OBJECTIVE: Somatostatin analogs inhibit neointimal hyperplasia and smooth muscle cell (SMC) proliferation in vivo. The gene transfer of somatostatin to endothelial cells (ECs) represents a potential means of local delivery of somatostatin to areas of arterial injury. This study tested the hypothesis that the retroviral gene transfer of somatostatin to ECs would inhibit SMC proliferation in vitro and evaluated the effects of somatostatin analogs on DNA synthesis and the growth of SMCs. METHODS: Media transfer and coculture were used to determine the effects of somatostatin-producing ECs on SMC proliferation in vitro. The effects of a variety of somatostatin isoforms and analogs on the proliferation of SMCs, mitogenesis of serum-restimulated quiescent SMCs, and arterial explants were measured. RESULTS: Despite the production of biologically relevant concentrations of somatostatin by ECs, no inhibition of SMC proliferation was noted. Somatostatin analogs inhibited DNA synthesis in arterial explants but did not inhibit either DNA synthesis or growth of cultured SMCs, which showed a likely effect of somatostatin on the initial transition in SMC phenotype. CONCLUSION: Somatostatin exerts inhibitory effects on SMC proliferation only during the early transition to a proliferative phenotype. There are significant differences between this in vivo transition and the standard serum-restimulated model of cultured SMCs. These differences may account for the failure of somatostatin to inhibit SMC proliferation in the standard in vitro models.


Subject(s)
Gene Transfer Techniques , Muscle, Smooth, Vascular/cytology , Somatostatin/genetics , Somatostatin/pharmacology , Animals , Cell Division/drug effects , Cells, Cultured , Coculture Techniques , DNA/biosynthesis , DNA/drug effects , Dogs , Endothelium, Vascular/cytology , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/physiology , Phenotype , Rats , Somatostatin/analogs & derivatives , Somatostatin/physiology
17.
Am J Physiol ; 276(2): G415-24, 1999 02.
Article in English | MEDLINE | ID: mdl-9950815

ABSTRACT

We previously observed that the trophic actions of gastrin (G17) on the AR42J rat acinar cell line are mediated by mitogen-activated protein kinase (MAPK)-induced c-fos gene transcription via protein kinase C (PKC)-dependent and -independent pathways. In this study, we further investigated the signaling pathways that target c-fos in response to G17. G17 led to a sixfold induction in luciferase activity in cells transfected with plasmids containing the -356+109 sequence of the murine c-fos promoter, which includes the Sis-inducible element (SIE), serum response element (SRE), and the Ca2+/cAMP response element (CRE) regulatory elements. Addition of either the selective PKC inhibitor GF-109203X or the MAPK/extracellular signal-regulated kinase inhibitor PD-98059 resulted in an 80% reduction in luciferase activity. G17 induced the transcriptional activity of both Elk-1 and Sap-1a, transcription factors that bind to the E26 transformation specific (Ets) DNA sequence of the SRE, and this effect was inhibited by both GF-109203X and PD-98059. Point mutations in the Ets sequence led to a 4-fold induction of c-fos transcription stimulated by G17 and to a 1.3-fold induction in response to epidermal growth factor (EGF). In contrast, mutations in the CA rich G (CArG) sequence of the SRE prevented transcriptional activation by both G17 and EGF. G17 induction of the Ets mutant construct was unaffected by either GF-109203X or PD-98059. Because activation of the SRE involves the small GTP-binding protein Rho A, we examined the role of Rho A in G17 induction of c-fos transcription. Inactivation of Rho A by either the specific inhibitor C3 or by expression of a dominant negative Rho A gene inhibited G17 induction of both the wild-type and the Ets mutant constructs by 60%. C3 also inhibited G17-stimulated AR42J cell proliferation. Thus G17 targets the c-fos promoter CArG sequence via Rho A-dependent pathways, and Rho A appears to play an important role in the regulation of the trophic action of G17.


Subject(s)
Gastrins/pharmacology , Genes, fos/genetics , Signal Transduction/physiology , Transcription, Genetic/drug effects , Transcription, Genetic/physiology , Animals , Calcium-Calmodulin-Dependent Protein Kinases/antagonists & inhibitors , Cells, Cultured , Enzyme Inhibitors/pharmacology , GTP-Binding Proteins/physiology , Luciferases/metabolism , Pancreas/cytology , Point Mutation/physiology , Promoter Regions, Genetic/genetics , Protein Kinase C/antagonists & inhibitors , Rats , Transfection , rho GTP-Binding Proteins
18.
Mol Endocrinol ; 13(1): 148-55, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9892020

ABSTRACT

Agouti-related protein (AGRP) is a naturally occurring antagonist of melanocortin action that is thought to play an important role in the hypothalamic control of feeding behavior. The exact mechanism of AGRP and Agouti protein action has been difficult to examine, in part because of difficulties in producing homogeneous forms of these molecules that can be used for direct binding assays. In this report we describe the application of chemical protein synthesis to the construction of two novel AGRP variants. Examination of the biological activity of the AGRP variants demonstrates that a truncated variant, human AGRP(87-132), a 46-amino acid variant based on the carboxyl-terminal cysteine-rich domain of AGRP, is equipotent to an 111-amino acid variant, mouse [Leu127Pro]AGRP (mature AGRP minus its signal sequence), in its ability to dose dependently inhibit alpha-MSH-generated cAMP generation at the cloned melanocortin receptors. Furthermore, deletion of the amino-terminal portion of the full-length variant did not alter the MCR subtype specificity of AGRP(87-132). Finally, iodination of human AGRP(87-132) provided a useful reagent with which the binding properties of AGRP could be analyzed. In both conventional and photoemulsion binding studies [125I]AGRP(87-132) was observed only to bind to cells expressing melanocortin receptors MC3R, MC4R, and MC5R. These results demonstrate that the residues critical for receptor binding, alpha-MSH inhibition, and melanocortin receptor subtype specificity are all located in the carboxyl terminus of the molecule. Because [Nle4, D-Phe7] (NDP)-MSH displaces the binding of [125I]AGRP(87-132) to MCRs and AGRP(87-132) displaces the binding of [125I]NDP-MSH, we conclude that these molecules bind in a competitive fashion to melanocortin receptors.


Subject(s)
Proteins/metabolism , Receptor, Melanocortin, Type 3 , Receptors, Corticotropin/metabolism , Agouti Signaling Protein , Agouti-Related Protein , Amino Acid Sequence , Animals , Cell Line , Cyclic AMP/metabolism , Humans , Intercellular Signaling Peptides and Proteins , Iodine Radioisotopes , Mice , Molecular Sequence Data , Peptide Fragments/chemical synthesis , Peptide Fragments/genetics , Peptide Fragments/metabolism , Proteins/chemical synthesis , Proteins/genetics , Receptors, Corticotropin/genetics , Receptors, Melanocortin , Transfection , alpha-MSH/pharmacology
19.
Hosp Med ; 59(2): 104-10, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9797883

ABSTRACT

Careful outpatient follow-up (including assessment of symptoms, risk stratification, secondary prevention and rehabilitation) is an essential component in the management of myocardial infarction.


Subject(s)
Ambulatory Care/organization & administration , Myocardial Infarction/rehabilitation , Female , Humans , Male , Myocardial Infarction/mortality , Myocardial Infarction/prevention & control , Postoperative Care , Risk Assessment , Treatment Outcome
20.
J R Army Med Corps ; 144(3): 131-7, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9819719

ABSTRACT

We monitored outpatient waiting times at UK military hospitals over an 18-month period (September 1996-March 1998). The highest mean waiting times for Consultant appointment were in urology (19 weeks) and orthopaedics (18 weeks). The lowest mean waiting times were in psychiatry (3 weeks), ENT surgery (5 weeks) and rheumatology (6 weeks). Waiting times for surgical specialties were around 50% higher than for medical specialties. The inter-hospital variability in waiting times was 260%. Military waiting list initiatives were introduced in 4 key specialties, but the majority of these initiatives only had a temporary impact in reducing outpatient waiting times. Waiting times reflect the accessibility of a hospital's services, and are a crude but easily measured indicator of one aspect of patient care. With a military population base, outpatient waiting times should be reduced to the lowest practicable level. The keys to achieving a long-term reduction in waiting times are proper staffing levels and the efficient management of clinics.


Subject(s)
Ambulatory Care/standards , Hospitals, Military , Outpatient Clinics, Hospital/standards , Quality Indicators, Health Care , Waiting Lists , Ambulatory Care/trends , Efficiency, Organizational , Health Services Research , Humans , Medicine , Outpatient Clinics, Hospital/trends , Seasons , Specialization , Specialties, Surgical , Time Factors , United Kingdom
SELECTION OF CITATIONS
SEARCH DETAIL
...